Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multi-center, Double-blind, Placebo-controlled, Group-comparison Study to Investigate Safety, Tolerability and Pharmacodynamics of BAY2253651 After Administration of a Single Nasal Dose in 60 Subjects With Obstructive Sleep Apnea and Open Exploratory Evaluation of Safety and Local Tolerability of Repeated Doses in Patients

Trial Profile

Randomized, Multi-center, Double-blind, Placebo-controlled, Group-comparison Study to Investigate Safety, Tolerability and Pharmacodynamics of BAY2253651 After Administration of a Single Nasal Dose in 60 Subjects With Obstructive Sleep Apnea and Open Exploratory Evaluation of Safety and Local Tolerability of Repeated Doses in Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs BAY-2253651 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Acronyms SANDMAN
  • Sponsors Bayer
  • Most Recent Events

    • 28 Jan 2019 Planned End Date changed from 17 Aug 2019 to 31 Mar 2020.
    • 28 Jan 2019 Planned primary completion date changed from 31 May 2019 to 31 Jan 2020.
    • 20 Aug 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top